Overview

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

1-(1-(3-((6-chloronaphthalen-2-yl)sulfonyl)-2-hydroxypropanoyl)piperidin-4-yl)tetrahydropyrimidin-2(1H)-one
Enoxaparin